How effective is Eculizumab in treating disease?

The active substance in Eculizumab (Eculizumab), the monoclonal antibody eculizumab, is also a protein designed to attach to the C5 complement protein. In patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), refractory generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD), complement proteins become overactive and damage the patient's own cells. By blocking the C5 complement protein and preventing the production of the terminal complement complex C5b-9, eculizumab prevents complement proteins from damaging cells, thereby helping to relieve the symptoms of these diseases.